Loading market dashboard
CelLBxHealth plc
ANPCYHealthcareOTCGB
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
CelLBxHealth PLC (AIM:CLBX, FRA:DWV) shares rose 8% to 0.99p after the AIM-listed circulating tumour cell specialist announced a research collaboration with The Royal Marsden NHS Foundation Trust to study a novel blood-based testing approach in advanced lung cancer patients. The two organisations will jointly conduct a clinical study in 200 patients with advanced non-small cell lung cancer (NSCLC), the most common form of the disease.
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), a specialist in circulating tumour cell (CTC) analysis, has announced a research collaboration with The Royal Marsden NHS Foundation Trust to study a novel blood-based testing approach in advanced lung cancer patients. The two organisations will jointly conduct a clinical study in 200 patients with advanced non-small cell lung cancer (NSCLC), the most common form of the disease.
